Monoamine oxidase A inhibitor

Berlin, I.S.S., Spreux-Varoquaux, O., Launay, J.M., Olivares, R., Millet, V., Lecrubier, Y., Puech, A.J. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. 58 444, 1995. 

Beriin I, Said S, Spreux-Varoquaux 0, Launay JM, Oiivares R, Miiiet V, Lecrubier Y, Puech AJ. (1995). A reversibie monoamine oxidase A inhibitor (mociobemide) faciiitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 58(4) 444-52. 

O. Curet, G. Damoiseau, N. Aubin, N. Sontag, V. Rovei, F.-X. Jarreau, Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile, J. Pharmacol. Exp. Ther. 277 (1996) 253-264. 

J. Wouters, F. Moureau, G. Evrard, J.-J. Koenig, S. Jegham, P. George, F. Durant, A reversible monoamine oxidase A inhibitors, befloxatone Structural approach of its mechanism of action, Bioorg. Med. Chem. 7 (1999) 1683-1693. 

In an early study, Insel et al. [1983b] compared the efficacy of CMI with that of clorgiline, a monoamine oxidase-A inhibitor, in a controlled crossover study of patients with OCD. Although CMl was effective, patients on clorgiline did not improve at all. Vallejo et al. [1992] conducted a controlled clinical trial of the efficacy of CMl and phenelzine in 30 patients with OCD. The authors reported improvement in both groups however, the lack of a placebo control and the small size of the study groups limit the applicability of these findings. Further studies on the therapeutic role of monoamine oxidase inhibitors in OCD, especially in OCD with comorbid panic disorder, are warranted. 

Bakish D The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with agoraphobia. J Clin Psychopharmacol 14 74-75, 1994... 

Bakish D, Saxena BM, Bowen R, et al Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 16 (suppl 2 S77-S82, 1993a Bakish D, Lapierre Y, Weinstein R, et al Ritanserin, imipramine and placebo in the treatment of dysthymic disorder. J Chn Psychopharmacol 13 409-414, 1993b Bakish D, Ravindran A, Hooper C, et al Psychopharmacological treatment response of patients with a DSM-111 diagnosis of dysthymic disorder. Psychopharmacol Bull 30 53-59, 1994... 

Montgomery SA, Brown RE, Clark M Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 168 768-771, 1996 Monti JM Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients. Br J Psychiatry Suppl 155 61-65, 1989 Monti JM, Alterwain P, Monti D The effects of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 20 201-208, 1990 Montkowski A, Holsboer F Absence of cognitive and memory deficits in transgenic mice with heterozygous disrupt of the brain-derived neurotrophic factor gene. J Psychiatr Res [in press)... 

Reul JMHM, Labeur MS, Grigoriadis DE, et al Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase A inhibitor moclobemide. Neuroendocrinology 60 509-519, 1994a... 

Pharmacologic doses of pyridoxine (vitamin B6 ) enhance the extracerebral metabolism of levodopa and may therefore prevent its therapeutic effect unless a peripheral decarboxylase inhibitor is also taken. Levodopa should not be given to patients taking monoamine oxidase A inhibitors or within 2 weeks of their discontinuance because such a combination can lead to hypertensive crises. 

Another example for biocatalytic reduction using glucose as the reductant, is the production of (R)-ethyl-4,4,4-trifluoro-3-hydroxybutanoate by Lonza [130]. It is a building block for pharmaceuticals such as Befloxatone, an anti-depressant monoamine oxidase-A inhibitor from Synthelabo. The process uses whole cells of Escheria coli that contain two plasmids. One carries an aldehyde reductase... 

Overdose of the selective monoamine oxidase A inhibitor moclobemide by itself rarely appears to give rise to serious problems, in contrast to overdose with conventional monoamine oxidase inhibitors, which can cause fatal 5HT toxicity. However, if patients take moclobemide together with serotonergic antidepressants, such as SSRIs or clomipramine, 5-HT toxicity is common. 5HT toxicity occurred in 11 of 21 patients who took overdoses of moclobemide and serotonergic agents but in only one of 33 patients who took moclobemide alone (46). Consistent with this, four patients died, presumably of 5HT toxicity, after co-ingesting 3,4-methyle-nedioxymethamphetamine (MDMA, ecstasy) and moclobemide (47). Massive ingestion of moclobemide (over 30 g) also appeared to be responsible for death in a suicide attempt in a 48-year-old man (48). The blood concentration of moclobemide measured at post mortem (498 pg/ml) was about 500 times the usual... 

There have been four deaths after interactions of moclobemide, a monoamine oxidase A inhibitor, with ecstasy (138). 

Dingemanse J, Guentert T, Gieschke R, Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. J Cardiovasc Pharmacol 1996 28(6) 856—861. 

Chimenti F, Bolasco A, Manna F, Seed D, Chimenti P, Granese A, et al. Synthesis, biological evaluation and 3D-QSAR of l,3,5-trisubstituted-4,5-dihydro-(lH)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr Med Chem 2006 13 1411-28. 

Acrivastine enhances the CNS depressant effects of alcohol and other CNS depressants. Overdosage with pseudoephedrine may cause palpitations, tachycardia, pressor activity, cardiac arrhythmias, or cardiovascular collapse. These agents should not be taken with monoamine oxidase A inhibitor (MAO A inhibitor), such as tranylcypromine. 

The continuous use of amphetamine causes tolerance, requiring higher doses, and hence there exists a high potential for its abuse. Amphetamine should not be used with a monoamine oxidase A inhibitor such as tranylcypromine, because the chance of inducing hypertension becomes magnified. 

Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995 29 292-332. 

Provost J-C, Funck-Brentano C, Rovei V, D Estanque J, Ego D, Jaillon P. Phmnacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther ( 992) 52,384-93. 

Schoerlin M-P, Mayersohn M, Hoevels B, E ers H, Dellenbach M, Pfefen J-P. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther (1991) 49, 32-8. 

Monoamine oxidase A inhibitor 5-HT receptor agonist 5-HT reuptake inhibitor... 

---